Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials

INTRODUCTION: The Janus kinase (JAK) inhibitor therapeutic class has shown significant clinical benefit in the treatment of rheumatoid arthritis (RA). We sought to gain insight into the mode of action and immunological effects of filgotinib, a JAK1 selective inhibitor, in active RA by analyzing secr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Rheumatol Ther
Main Authors: Tarrant, Jacqueline M., Galien, René, Li, Wanying, Goyal, Lovely, Pan, Yang, Hawtin, Rachael, Zhang, Wangshu, Van der Aa, Annegret, Taylor, Peter C.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Healthcare 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7021851/
https://ncbi.nlm.nih.gov/pubmed/31912462
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40744-019-00192-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados